SOVREMENNAYA PEDIATRIYA.2016.5(77):67-70; doi10.15574/SP.2016.77.67 

Prescribtion of the levocarnitin for the treatment of secondary cardiomyopathy in infants 

Tokarchuk N. I., Vyzhga Y. V.,  Starynets L.S.

N.I. Pirogov Vinnitsa National Medical University, Ukraine

Vinnytsia Regional Children's Clinical Hospital, Ukraine 

Actuality of the problem of metabolic myocardial disorders in pediatrics appears due to the spread of the pathology, increased frequency of the metabolic diseases at the background of other somatic pathology in children. The separate place in practical work is given to the problem of secondary cardiomyopathy — non inflammatory myocardial injury with metabolic disorder pathogenesis, due to energy generation and convertation its by myocardium to mechanical work with the next development of the dystrophic changes with development of the heart failure.

The goal of the study. To evaluate effect of the treatment with levocarnitin of the secondary cardiomyopathy in infants.

Materials and methods. We checked up 42 infants that passed treatment in Vinnitsya regional children's hospital at the department for infants with an estimated diagnose of protein-energetic insufficiency of II and III stages. At the background of clinical data and results of the laboratory and instrumental study supervise diagnose of the secondary cardiomyopathy was estimated. All kids received treatment of the main disease and cardiomyopathy with prescription of levocarnitin (Agvantar) in solution for the following 4 weeks. In a months we checked results of the laboratory!instrumental signs of the cardial system and lipid metabolism.

Results of the study. In a 4 weeks of the treatment content of the serum cholesterol in infants with protein-energetic insufficiency II and III stages was almost the same, but still less than results of the healthy children. During the period of one months of the levocarnitin intake we recived decreased amount of the changed T wave, depression of the ST that generally indicated disappearance of the repolarzation disorders of the myocardium in infants. According to the results of the Echo-CG we got normalization of the ejection fraction, decreased frequency of the mitral prolabing that explained by normalization of the constrictive ability of the left ventricle myocardium.

Conclusion. At the background of the cardiometabolic treatment with levocarnitin (Agvantar) in infants with secondary cardiomyopathy we received stabilizing of the functional condition of the cardio-vascular system, improvement of the electrical function of the heart.

Keywords: secondary cardiomyopathy, levocarnitin, infants

REFERENCES

1. Vorobyova OV, Mukhina NI, Vasilenko BA, Gudova OA, Levchenko LA, Podolyaka VL, Mukhin AS. 2011. Experience of L-carnitine in premature infants. Sovremennaya pediatriya. 6(40): 72—74.

2. Leonteva IV, Suhorukov VS. Znachenie metabolicheskih narusheniy v geneze kardiomiopatiy i vozmozhnosti primeneniya L-karnitina dlya terapevticheskoy korrektsii. Vestnik pediatrich farmakol i nutritsiol. 2: 37—43.

3. Mutafyan OA. 2008. Kardiomiopatii u detey i podrostkov. Sankt-Peterburg, Dialekt: 272.

4. Cox GF, Sleeper LA, Lowe AM et al. 2014. Factors associated with establishing a causal diagnosis for children with cardiomyopathy. Pediatrics. 118: 1519—1531. http://dx.doi.org/10.1542/peds.2006-0163; PMid:17015543

5. Helton E, Darragh R, Francis P et al. 2015. Metabolic aspects of myocardial disease and a role for L-carnitine in the treatment of childhood cardiomyopathy. Pediatrics. 125: 1260—70.

6. Azevedo VM, Albanesi Filho FM, Santos MA et al. 2013. The role of L-carnitine in nutritional status and echocardiographic parameters in idiopathic dilated cardiomyopathy in children. J Pediatr (Rio J). 81(5): 368—72. http://dx.doi.org/10.1590/S0021-75572005000600005; http://dx.doi.org/10.2223/JPED.1387; PMid:16247537

7. Winter SC, Buist NR. 2014. Cardiomyopathy in childhood, mitochondrial dysfunction, and the role of L-carnitine. Am Heart J. 139: 63—9. http://dx.doi.org/10.1067/mhj.2000.103935